Tags

Type your tag names separated by a space and hit enter

Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium.
Br J Rheumatol. 1996 Apr; 35 Suppl 1:39-43.BJ

Abstract

A multicentre, double-blind, randomized study was conducted in patients with osteoarthritis (OA) of the hip or knee in order to compare the efficacy and safety of the new cyclooxygenase-2 (COX-2) inhibitor, meloxicam, with diclofenac sodium, a conventional treatment for this condition. Three hundred and thirty-six patients were treated with oral meloxicam 7.5 mg once daily or diclofenac 100 mg slow release once daily for 6 months. There were no significant differences between the treatment groups with respect to overall pain, pain on movement, global efficacy or quality of life scores at the end of treatment, all of which showed good levels of improvement. Sixty-six patients were withdrawn after the start of the double-blind phase due to adverse events (n = 21, meloxicam; n = 31, diclofenac) or to lack of efficacy (seven in each group). The median of dose paracetamol taken concomitantly was statistically significantly lower in the meloxicam group than in the diclofenac group (185 vs 245 mg/day; P = 0.0123) with a comparable proportion of patients taking concomitant paracetamol therapy in both groups. Both drugs were well tolerated, although severe adverse events, treatment withdrawal and clinically significant laboratory abnormalities were more common with diclofenac than with meloxicam. Thus, meloxicam 7.5 mg is a safe and effective treatment for OA of the hip and knee which demonstrates a trend towards an improved safety profile compared with diclofenac.

Authors+Show Affiliations

Great Western Medical, Knightswood, Glasgow.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

8630635

Citation

Hosie, J, et al. "Meloxicam in Osteoarthritis: a 6-month, Double-blind Comparison With Diclofenac Sodium." British Journal of Rheumatology, vol. 35 Suppl 1, 1996, pp. 39-43.
Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br J Rheumatol. 1996;35 Suppl 1:39-43.
Hosie, J., Distel, M., & Bluhmki, E. (1996). Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. British Journal of Rheumatology, 35 Suppl 1, 39-43.
Hosie J, Distel M, Bluhmki E. Meloxicam in Osteoarthritis: a 6-month, Double-blind Comparison With Diclofenac Sodium. Br J Rheumatol. 1996;35 Suppl 1:39-43. PubMed PMID: 8630635.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. AU - Hosie,J, AU - Distel,M, AU - Bluhmki,E, PY - 1996/4/1/pubmed PY - 1996/4/1/medline PY - 1996/4/1/entrez SP - 39 EP - 43 JF - British journal of rheumatology JO - Br. J. Rheumatol. VL - 35 Suppl 1 N2 - A multicentre, double-blind, randomized study was conducted in patients with osteoarthritis (OA) of the hip or knee in order to compare the efficacy and safety of the new cyclooxygenase-2 (COX-2) inhibitor, meloxicam, with diclofenac sodium, a conventional treatment for this condition. Three hundred and thirty-six patients were treated with oral meloxicam 7.5 mg once daily or diclofenac 100 mg slow release once daily for 6 months. There were no significant differences between the treatment groups with respect to overall pain, pain on movement, global efficacy or quality of life scores at the end of treatment, all of which showed good levels of improvement. Sixty-six patients were withdrawn after the start of the double-blind phase due to adverse events (n = 21, meloxicam; n = 31, diclofenac) or to lack of efficacy (seven in each group). The median of dose paracetamol taken concomitantly was statistically significantly lower in the meloxicam group than in the diclofenac group (185 vs 245 mg/day; P = 0.0123) with a comparable proportion of patients taking concomitant paracetamol therapy in both groups. Both drugs were well tolerated, although severe adverse events, treatment withdrawal and clinically significant laboratory abnormalities were more common with diclofenac than with meloxicam. Thus, meloxicam 7.5 mg is a safe and effective treatment for OA of the hip and knee which demonstrates a trend towards an improved safety profile compared with diclofenac. SN - 0263-7103 UR - https://www.unboundmedicine.com/medline/citation/8630635/Meloxicam_in_osteoarthritis:_a_6_month_double_blind_comparison_with_diclofenac_sodium_ L2 - https://medlineplus.gov/osteoarthritis.html DB - PRIME DP - Unbound Medicine ER -